As of March 31, 2026, Acuvi AB carries a market capitalization of 367.57M, placing it among publicly traded companies globally. Its enterprise value stands at 405.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 367.57M |
| Enterprise Value | 405.20M |
Acuvi AB's next confirmed earnings release is scheduled for February 25, 2027.
| Earnings Date | 2/25/2027 |
As of March 31, 2026, Acuvi AB has 33.36M shares outstanding.
| Shares Outstanding | 33.36M |
These figures are as of March 31, 2026. The price-to-sales ratio is 1.72, and the price-to-book ratio stands at 0.88.
| PS Ratio | 1.72 |
| PB Ratio | 0.88 |
| P/TBV Ratio | 6.56 |
| P/FCF Ratio | 19.81 |
| P/OCF Ratio | 14.73 |
As of March 31, 2026, Acuvi AB trades at an EV/EBITDA multiple of 19.50 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.99 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 405.20M versus a market cap of 367.57M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.99 |
| EV / EBITDA | 19.50 |
As of March 31, 2026, Acuvi AB maintains a current ratio of 2.30, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.85, indicating elevated leverage, while an interest coverage ratio of 3.43 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.30 |
| Quick Ratio | 0.45 |
| Debt / Equity | 14.85 |
| Debt / EBITDA | 2.97 |
| Interest Coverage | 3.43 |
Over the twelve months ended March 31, 2026, Acuvi AB posted a negative return on equity (ROE) of -4.47, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.53, reflecting losses generated across the asset base. The company generates approximately 3.80M in revenue per employee across its workforce of 53.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.29 indicates how many times Acuvi AB sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -4.47 |
| Return on Assets (ROA) | -3.53 |
| Revenue Per Employee | 3.80M |
| Employee Count | 53.50 |
| Inventory Turnover | 1.29 |
Over the twelve months ended March 31, 2026, Acuvi AB recorded 1.52M in income tax expense. The company reported a pretax loss of -17.48M and -19.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 1.52M |
As of the close on November 17, 2026, Acuvi AB's stock has declined approximately 71.66% over the past 52 weeks. The 50-day moving average sits at 6.75, while the 200-day moving average is 10.51.
| 52-Week Price Change | -71.66% |
| 50-Day Moving Average | 6.75 |
| 200-Day Moving Average | 10.51 |
Over the twelve months ended March 31, 2026, Acuvi AB generated 203.17M in revenue and converted that into -19.00M in net income, yielding earnings per share of -0.60. EBITDA reached 20.78M, while operating income came in at -11.76M.
| Revenue | 203.17M |
| Gross Profit | 125.85M |
| Operating Income | -11.76M |
| Pretax Income | -17.48M |
| Net Income | -19.00M |
| EBITDA | 20.78M |
| EBIT | -11.76M |
| Earnings Per Share (EPS) | -0.60 |
As of March 31, 2026, Acuvi AB holds 24.09M in cash and equivalents against 61.71M in total debt, resulting in a net debt position of 15.13M. Total book value stands at 415.52M, with working capital of 70.00M providing operational flexibility.
| Cash & Cash Equivalents | 24.09M |
| Total Debt | 61.71M |
| Net Debt | 15.13M |
| Equity (Book Value) | 415.52M |
| Book Value Per Share | 12.46 |
| Working Capital | 70.00M |
Acuvi AB produced 23.75M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -6.09M in capital expenditures, free cash flow totaled 17.66M - equivalent to 0.56 per share.
| Operating Cash Flow | 23.75M |
| Capital Expenditures | -6.09M |
| Free Cash Flow | 17.66M |
| FCF Per Share | 0.56 |
Over the twelve months ended March 31, 2026, Acuvi AB posted a gross margin of 61.94, reflecting its pricing power and cost economics. The operating margin of -5.79 and net profit margin of -9.35 provide insight into operational efficiency.
| Gross Margin | 61.94 |
| Operating Margin | -5.79 |
| Pretax Margin | -8.60 |
| Profit Margin | -9.35 |
| EBITDA Margin | 10.23 |
These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 5.05, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 10.37, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Acuvi AB shareholders.
| Shareholder Yield | 10.37 |
| FCF Yield | 5.05 |
Acuvi AB's most recent stock split took place on May 31, 2024 with a 497:500 split ratio.
| Last Split Date | 5/31/2024 |
| Split Ratio | 497:500 |
As of March 31, 2026, Acuvi AB has an Altman Z-Score of 2.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.92 |
Already premium?